A recent study is challenging long-held assumptions about how GLP-1s help people with knee arthritis, revealing that they may offer therapeutic benefits that extend far beyond simple weight reduction.
The research, published February 9 in a scientific journal, examined semaglutide’s effects on knee osteoarthritis and discovered something unexpected: the medication appears to restore cartilage through metabolic mechanisms that operate independently of weight loss.
“We used to think that the benefit of GLP-1 dr**s (like Ozempic) was dependent on weight loss. Now we know so many health benefits have little to do with that,” wrote Eric Topol on social media, physician-scientist and founder and director of Scripps Research Translational Institute.
Topol emphasized the dual nature of the evidence: “Independent of weight loss, semaglutide (Ozempic) improves knee arthritis by cartilage restoration, in both the mouse model and a small randomised clinical trial.”
Independent of weight loss, semaglutide (Ozempic) improves knee arthritis by cartilage restoration, in both the mouse model and a small randomized clinical trial @Cell_Metabolism https://t.co/fqbrQQYfRt pic.twitter.com/gy2LobAA8H
— Eric Topol (@EricTopol) February 9, 2026
This discovery comes from the STEP 9 trial, a comprehensive study involving 407 participants across 61 sites in 11 countries. The research focused on adults experiencing severe knee pain from moderate osteoarthritis who also had obesity, defined as a body mass index of 30 kilograms per square meter (kg/m2) or higher.
The trial’s results were striking. Over 68 weeks, participants taking semaglutide 2.4 milligrams weekly experienced a 10.5% reduction in body weight compared to those receiving placebo, which is approximately a 25-pound difference. The average participant weighed 239 pounds (108.6 kilograms) at the study’s start.
But weight loss wasn’t the only significant outcome. Participants reported meaningful improvements in pain intensity, measured using the Western Ontario and McMaster Universities Osteoarthritis Index, a validated assessment tool. The semaglutide group experienced a 41.7-point reduction in pain scores on a 0-100 scale, compared to a 27.5-point reduction in the placebo group.
Perhaps more importantly for daily quality of life, functional improvements were substantial. About 50% of participants taking semaglutide showed clinically meaningful improvement in physical function scores, compared to 29% in the placebo group. This translates to real-world benefits in mobility and daily activities.
The study population reflected typical osteoarthritis patients: the average age was 56 years, with women comprising 81.6% of participants. At baseline, participants had severe pain, with average scores of 70.9 on the normalized pain scale. All participants received counseling on reduced-calorie diets and physical activity alongside their assigned medication.
The medication was generally well-tolerated, with participants gradually increasing their dose over 16 weeks to reach the target amount. By the end of the treatment period, nearly 90% of those taking semaglutide remained on the 2.4 milligram dose.
Gastrointestinal effects were the most common side effects leading to discontinuation, though only 6.7% of participants stopped taking semaglutide due to adverse events, compared to 3% in the placebo group. Serious adverse events occurred at similar rates in both groups.
The implications of this research extend beyond confirming that weight loss helps with arthritis pain, something already established in medical literature. The novel finding that metabolic restoration may occur independently of weight reduction suggests GLP-1s might work through multiple pathways to benefit joint health.
For patients living with both obesity and knee osteoarthritis, these findings offer encouragement. Weight loss of approximately 5% has previously been shown to produce clinically significant improvements in function and pain for this population. The STEP 9 trial demonstrated that semaglutide, combined with lifestyle modifications, can help achieve and surpass this threshold.
The research does come with important caveats. The study excluded many individuals, including those with diabetes, chronic widespread pain, or recent opioid use, which limits how broadly the results can be applied.
Additionally, the trial wasn’t designed to determine whether semaglutide has direct pain-relieving properties beyond those related to weight loss and metabolic changes.
Questions also remain about long-term sustainability. Previous research has shown that when semaglutide is discontinued, weight regain often occurs, with people regaining about two-thirds of lost weight within a year. Whether the pain and functional benefits persist after stopping the medication remains unknown.
The study’s design, while rigorous, had some potential weaknesses. The substantial weight loss in the treatment group likely made it obvious to participants which medication they were receiving, potentially influencing their subjective pain reports.
Despite these limitations, participants not only reported less pain but also showed improvements in physical function, stiffness reduction, and increased walking distance in six-minute walking tests.
Use of pain medications decreased in both groups during the study, with a more pronounced reduction among those taking semaglutide. However, this group had higher baseline use of acetaminophen, which could partially explain the difference.
